A Randomized, Phase III Study ComparingConventional Dose Treatment Using a Combination of Lenalidomide,Bortezomib and Dexamethasone (RVD) to High-Dose Treatment withPeripheral Stem Cell Transplant in the Initial Management of Myeloma inPatients up to 65 Years of Age
A study for patients with newly diagnosed multiple myeloma using study drugs lenalidomide, bortezomib and Dexamethason
Sponsor: Dana Farber Cancer Institute
Enrolling: Male and Female Patients
IRB Number: AAAN7006
U.S. Govt. ID: NCT01208662
Contact: Ryan Shelton: 212-304-5485 / rs3323@columbia.edu
Additional Study Information: The purpose of this research study is to explore the drug combination, lenalidomide, bortezomib, and dexamethasone alone or when combined with autologous stem cell transplantation to see what side effects it may have and how well it works for treatment of newly diagnosed multiple myeloma.
This study is closed
Investigator
Suzanne Lentzsch, MD
Do You Qualify?
Have you been diagnosed with multiple myeloma? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Ryan Shelton
rs3323@columbia.edu
212-304-5485
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE